Опубликовать статью

Информационное партнерство

Инфоресурсы

Контакты

«

Vol. 22, Art. 36 (pp. 527-539)    |    2021       

»

Impact of age on results of autologous hematopoietic stem cell transplantation in patients with multiple myeloma

Mikhailov E.S.1, Salogub G.N.2, Bessmeltsev S.S.1

1Russian Research Institute of Hematology and Transfusiology
2Federal Almazov North-West Medical Research Centre

Brief summary

Introduction. Despite the development of new target drugs for treatment of multiple myeloma, autologous stem cell transplantation still has important role in therapy of this disease. Decision of up-front therapy based on eligibility for stem cell transplantation. Age of patient can be a contraindication for autologous stem cell transplantation. Aim. To assess the impact of age on results of autologous stem cell transplantation in patients with multiple myeloma Materials & methods. The present retrospective study enrolled 76 patients with multiple myeloma. 9 patients were 65+ years old (11,8%). The analysis was focused on frequency of infectious complications, duration of hospitalization and 1-year overall survival. Results. There were no cases of transplantation-related mortality. In the group of patients over 65 years of the age infectious complications developed in 4 patients (44%). There were 2 cases of death in 1 year after stem cell transplantation, all cases were due to disease progression. Conclusion. Patients over 65 can be potential candidates for stem cell transplantation. According to current available data autologous stem cell transplantation could be recommended for patients older than 70 years old without significant concomitant pathology.


Key words

multiple myeloma, autologous stem cell transplantation, comorbidity, age

Reference list

1. Multiple myeloma. NCCN Guidelines Version 1.2022. Availiable at: https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf (accessed 12 September 2021)


2. Dimopoulos M.A. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up / Dimopoulos M.A et al. // Annals of Oncology - 2021. - 32 (3) - P. 309-322


3. Mnojestvennaya mieloma. Klinicheskie rekomendacii. URL: https://rusoncohem.ru/wp-content/uploads/2019/11/Mnozhestvennaya-mieloma.pdf (data obrasheniya 12 sentyabrya 2021 goda)


4. Liu Y. Costs and in-Hospital Mortality Rates in Autologous Stem Cell Transplant for Multiple Myeloma: An Analysis of the Nationwide Inpatient Sample (NIS) Database/ Liu Y. et al. // Blood - 2017 - 130 (7): 2108


5. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Published: November 27, 2017. Availiable at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf (accessed 12 September 2021)


6. Stettler J. Autologous stem cell transplantation in elderly multiple myeloma patients with multiple myeloma: evaluation of its safety and efficacy/ Stettler J. et al/ Leuk Lymphoma - 2017 - 58 (5) - P. 1076-1083


7. Siegel D.S. Age is not a prognostic variable with autotransplants for multiple myeloma/ Siegel D.S. et al/ Blood - 1999 - 93 (1) - P. 51-54


8. Kumar S. Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis/Kumar S. et al/ Am J Hematol. - 2008 - 83 (8) - P. 614-7


9. Sharma M. Older patients with myeloma derive similar benefit from autologous transplantation/ Sharma M et al/ Biol Blood Marrow Transplant - 2014 - 20 (11) - P. 1796-803


10. Auner H.W. Trends in autologous hematopoietic cell transplantation for multiple myeloma in EuropeL increased use and improved outcomes in elderly patient in recent years/ Auner H.W. et al/ Bone Marrow Transplant. - 2015 - 50 (2) - P. 209-15


11. Bernard R.St. Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure/ Bernard R.St. et al/ Bone Marrow Transplant. - 2015 - 50 (1) - P. 95-9.


12. Bashir Q. Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 years/ Bashir Q. et al/ Leuk Lymphoma - 2019 - 60 (14) - P. 3536 - 3543


13. Bessmelcev S. S. Mnojestvennaya mieloma. Rykovodstvo dlya vracheĭ/ Bessmelcev S. S., Abdylkadirov K. M. ? M.: MK, 2016-504 s.